New Lung Cancer Therapy May Target Previously Untreatable Tumors (Memorial Sloan Kettering Cancer Center)

Although some lung cancer patients have benefited from developments in precision therapy, those with mutations in a gene called KRAS have not. Now Memorial Sloan Kettering Cancer Center researchers are developing uses for a compound that targets a common KRAS mutation in lung cancer. Memorial Sloan Kettering Cancer Center is one of the 26 NCCN Member Institutions. ...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

Therapeutic efficacy of hydrogen‑rich saline alone and in combination with PI3K inhibitor in non‑small cell lung cancer. Mol Med Rep. 2018 Jun 14;: Authors: Jiang Y, Liu G, Zhang L, Cheng S, Luo C, Liao Y, Guo S Abstract The aim of the present study was to investigate the effects of combination therapy of LY294002, a specific inhibitor of phosphatidylinositol 3‑kinase (PI3K), with hydrogen‑rich saline on the proliferation and apoptosis of the non‑small cell lung cancer (NSCLC) A549 cell line and the mechanisms underpinning this. Excessive production of reactive oxygen species (...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
ConclusionMajor changes of PD-L1 expression in tumor cells were observed in 38% of NSCLC patients who received anticancer treatments. And, treatments with EGFR-TKI may increase PD-L1 expression in NSCLC patients harboringEGFR mutations.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conclusions Neither patient nor physician race was significantly associated with risk estimation or surgical recommendations. These findings do not provide an explanation for documented racial disparities in lung cancer therapy. Further investigation is needed to identify mechanism underlying these disparities.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
CONCLUSIONS: Neither patient nor physician race was significantly associated with risk estimation or surgical recommendations. These findings do not provide an explanation for documented racial disparities in lung cancer therapy. Further investigation is needed to identify mechanism underlying these disparities. PMID: 29902464 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
Authors: Tabei A, Watanabe M, Ikeuchi H, Nakasatomi M, Sakairi T, Kaneko Y, Maeshima A, Kaira K, Hirato J, Nojima Y, Hiromura K Abstract Nivolumab is an anti-programmed cell death-1 (PD-1) antibody that is utilized as an immune checkpoint inhibitor (ICI) for cancer therapy. We herein present the case of a 57-year-old man who developed acute kidney injury during treatment with nivolumab for lung cancer. A renal biopsy revealed acute tubulointerstitial nephritis. Immunohistochemical staining demonstrated marked infiltration of macrophages and T cells together with mild B cell infiltration. Of note, strong CD163+ M2 m...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
AbstractBackgroundThe clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor types, including lung cancer. However, the immunological profile of non –small cell lung carcinoma (NSCLC) treated with neoadjuvant chemotherapy (NCT) is not yet fully characterized, and it may be therapeutically important. The aim of this retrospective study was to characterize and quantify PD-L1/PD-1 expression and tumor-associated immune cells (TAICs) in surgically resected NSCLCs from patien...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: This paper highlights that these 3 lung cancer subtypes may be distinct diseases at the genetic level. In the era of precision medicine, we feel that these genomic differences will be of utmost importance in the choice of lung cancer therapy in the future.Hum Hered 2017 –18;83:65–70
Source: Human Heredity - Category: Genetics & Stem Cells Source Type: research
Source: Journal of Biomedical Nanotechnology - Category: Nanotechnology Authors: Tags: Research Articles Source Type: research
Publication date: September 2018 Source:Biomedicine & Pharmacotherapy, Volume 105 Author(s): Zizheng Song, Yan Shi, Quanli Han, Guanghai Dai Special targeted therapy like endothelial growth factor receptor (EGFR) targeted therapy is available for the treatment of advanced non-small cell lung cancer (NSCLC). Biodegradable core-shell lipid-polymer hybrid nanoparticles (LPNs) can combine the beneficial properties of lipid and polymeric NPs for controlled drug delivery. In the present study, epidermal growth factor (EGF) conjugated LPNs were fabricated to co-deliver docetaxel (DTX) and resveratrol (RSV). In vitro and in v...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 24 May 2018 Source:Cancer Cell Author(s): Nobuaki Takahashi, Hsing-Yu Chen, Isaac S. Harris, Daniel G. Stover, Laura M. Selfors, Roderick T. Bronson, Thomas Deraedt, Karen Cichowski, Alana L. Welm, Yasuo Mori, Gordon B. Mills, Joan S. Brugge Cancer cell survival is dependent on oxidative-stress defenses against reactive oxygen species (ROS) that accumulate during tumorigenesis. Here, we show a non-canonical oxidative-stress defense mechanism through TRPA1, a neuronal redox-sensing Ca2+-influx channel. In TRPA1-enriched breast and lung cancer spheroids, TRPA1 is critical for survival of i...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Lung Cancer